Jens Oscar Faber

Medicine & Life Sciences

1. Heart Failure 100%
2. Type 2 Diabetes Mellitus 89%
3. empagliflozin 60%
4. Thyroxine 60%
5. Liraglutide 60%
6. Polycystic Ovary Syndrome 59%
7. Brain Natriuretic Peptide 59%
8. Randomized Controlled Trials 56%
9. Placebos 55%
10. Thyroid Gland 53%
11. Hypoglycemia 52%
12. Natriuretic Peptides 49%
13. Cardiovascular Diseases 46%
14. Atrial Natriuretic Factor 44%
15. pro-brain natriuretic peptide (1-76) 41%
16. Type 1 Diabetes Mellitus 40%
17. Hypothyroidism 38%
18. Hyperthyroidism 37%
19. Cross-Over Studies 36%
20. copeptins 35%
21. Triiodothyronine 32%
22. Denmark 32%
23. Mineralocorticoid Receptor Antagonists 32%
24. Adrenomedullin 32%
25. Testosterone Congeners 32%
26. Eplerenone 30%
27. Therapeutics 30%
28. Athletes 29%
29. Mortality 29%
30. Glucose 29%
31. Fats 29%
32. Insulin Resistance 29%
33. Body Composition 27%
34. Pressure 26%
35. Exercise 26%
36. Biomarkers 26%
37. Lacunar Stroke 26%
38. Myocardial Ischemia 25%
39. Blood Pressure 25%
40. Population 25%
41. Elderly 23%
42. Heart Rate 23%
43. Insulin-Like Growth Factor I 23%
44. Testosterone 23%
45. Cohort Studies 22%
46. Body Mass Index 22%
47. Serum 21%
48. Iodide Peroxidase 21%
49. Left Ventricular Function 21%
50. Pain 21%